NYSE:AGN - Allergan Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$175.66 -0.05 (-0.03 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$174.20
Today's Range$174.81 - $176.67
52-Week Range$142.81 - $256.80
Volume1.08 million shs
Average Volume2.88 million shs
Market Capitalization$60.07 billion
P/E Ratio10.74
Dividend Yield1.63%
Beta1.13
Allergan logoAllergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone862-261-7000

Debt

Debt-to-Equity Ratio0.36
Current Ratio1.10
Quick Ratio0.94

Price-To-Earnings

Trailing P/E Ratio10.74
Forward P/E Ratio10.92
P/E Growth1.27

Sales & Book Value

Annual Sales$15.94 billion
Price / Sales3.74
Cash Flow$39.7421 per share
Price / Cash4.42
Book Value$207.19 per share
Price / Book0.85

Profitability

EPS (Most Recent Fiscal Year)$16.35
Net Income$-4,125,500,000.00
Net Margins-11.94%
Return on Equity8.53%
Return on Assets5.00%

Miscellaneous

Employees17,800
Outstanding Shares339,060,000
Market Cap$60,065.18

The Truth About Cryptocurrencies

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan declared a quarterly dividend on Thursday, May 3rd. Shareholders of record on Friday, May 18th will be paid a dividend of $0.72 per share on Friday, June 15th. This represents a $2.88 dividend on an annualized basis and a yield of 1.64%. The ex-dividend date of this dividend is Thursday, May 17th. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan announced that its Board of Directors has approved a stock repurchase program on Tuesday, September 26th 2017, which permits the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its stock is undervalued.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) issued its quarterly earnings results on Monday, April, 30th. The company reported $3.74 EPS for the quarter, beating analysts' consensus estimates of $3.36 by $0.38. The company earned $3.67 billion during the quarter, compared to analyst estimates of $3.59 billion. Allergan had a positive return on equity of 8.53% and a negative net margin of 11.94%. The company's revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the prior year, the company posted $3.35 EPS. View Allergan's Earnings History.

When is Allergan's next earnings date?

Allergan is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan updated its FY18 earnings guidance on Monday, April, 30th. The company provided earnings per share guidance of $15.65-16.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.66. The company issued revenue guidance of $15.15-15.35 billion, compared to the consensus revenue estimate of $15.24 billion.Allergan also updated its Q2 guidance to $4.00-4.20 EPS.

What price target have analysts set for AGN?

21 equities research analysts have issued 1-year price objectives for Allergan's stock. Their forecasts range from $160.07 to $265.00. On average, they expect Allergan's share price to reach $212.1616 in the next twelve months. This suggests a possible upside of 20.8% from the stock's current price. View Analyst Ratings for Allergan.

What is the consensus analysts' recommendation for Allergan?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:
  • 1. According to Zacks Investment Research, "2018 could prove to be a tough year for Allergan with the company facing loss of exclusivity for many products including Namenda XR and Restasis. Also, new competition for key growth drivers, Restasis and Linzess, is a concern. Nonetheless, Allergan boasts dominant growth franchises across several therapeutic areas. Key products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar will continue to support sales. Allergan also boasts a strong branded pipeline with meaningful data readouts expected in 2018. Biosimilars also represent significant opportunity.  In late 2017, Allergan announced cost-cutting efforts to protect it from potential revenue declines. Allergan’s share price has picked up after underperforming the industry in the second half of 2017. Estimates have gone up slightly of the Q2 earnings release. The company has a positive record of earnings surprises in recent quarters." (7/17/2018)
  • 2. Mizuho analysts commented, "We raise PT to $176 from $150 on stronger Botox expectations in both migraine and cosmetic indications, and view recent investor activism as positive to AGN." (6/8/2018)
  • 3. Cantor Fitzgerald analysts commented, "This morning AGN reported a high quality 1Q18 EPS beat and raised its 2018 EPS guidance. This is clearly good news for the company, but we would note that a beat and raise was widely anticipated by the Street since AGN’s setup looked conservative heading into the year. Furthermore, if Restasis generics do not enter the market in 2018, we could see AGN continuing to beat its financial guidance throughout the year." (4/27/2018)

Who are some of Allergan's key competitors?

Who are Allergan's key executives?

Allergan's management team includes the folowing people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 63)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)

Has Allergan been receiving favorable news coverage?

News articles about AGN stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Allergan earned a news sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the company an impact score of 46.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Allergan's major shareholders?

Allergan's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Retirement Systems of Alabama (0.11%), Confluence Investment Management LLC (0.10%), Bank of Montreal Can (0.10%), Swedbank (0.07%), Gateway Investment Advisers LLC (0.07%) and Cacti Asset Management LLC (0.06%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.

Which institutional investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Swedbank, Bank of Montreal Can, Meag Munich Ergo Kapitalanlagegesellschaft MBH, American National Bank, Gofen & Glossberg LLC IL, First National Bank of Omaha, Confluence Investment Management LLC and Park National Corp OH. View Insider Buying and Selling for Allergan.

Which institutional investors are buying Allergan stock?

AGN stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Neville Rodie & Shaw Inc., Assenagon Asset Management S.A., XR Securities LLC, Kempner Capital Management Inc., State of Alaska Department of Revenue, Campbell & CO Investment Adviser LLC and Fox Run Management L.L.C.. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $175.66.

How big of a company is Allergan?

Allergan has a market capitalization of $60.07 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]


MarketBeat Community Rating for Allergan (NYSE AGN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  1,081 (Vote Outperform)
Underperform Votes:  489 (Vote Underperform)
Total Votes:  1,570
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.